Exicure, Inc. XCUR
1.01 USD -0.01 (-0.98%)
At closeNov 3, 2026, 4:00 PM EST
1.01 0.00 0.00%
After hours · Nov 3, 4:00 PM ET
0.9999 Day range 1.03
0.875 52-week range 9.48
- YTD
- -81.37%
- 1 year
- -76.01%
News
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers iSpecimen (NASDAQ:ISPC) stock moved upwards by 16.1% to $0.92 during Thursday's after-market session. The company's market cap stands at $2.2 million. CareDx (NASDAQ:CDNA) stock rose 15.0% to…
defenseworld.net Comparing Shattuck Labs (NASDAQ:STTK) & Exicure (NASDAQ:XCUR) Shattuck Labs (NASDAQ: STTK - Get Free Report) and Exicure (NASDAQ: XCUR - Get Free Report) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two…
benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session Gainers Alaunos Therapeutics (NASDAQ:TCRT) shares moved upwards by 30.0% to $2.08 during Thursday's after-market session. The company's market cap stands at $3.2 million. cbdMD (AMEX:YCBD) stock…
benzinga.com Exicure Receives Nasdaq Extension Through December 2 To Regain Compliance As previously disclosed, on June 5, 2026, Nasdaq notified the Company that it did not satisfy Nasdaq Listing Rule 5550(b)(1), which requires a listed company to maintain a minimum of $2.5 million in…
globenewswire.com Exicure Receives Nasdaq Extension to Regain Compliance with Stockholders' Equity Requirement WILMINGTON, Del., Sept. 16, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that, on September 10, 2026, it received a letter from the Listing…
benzinga.com 12 Health Care Stocks Moving In Friday's Intraday Session Gainers Werewolf Therapeutics (NASDAQ:HOWL) shares increased by 108.1% to $0.9 during Friday's regular session. The market value of their outstanding shares is at $20.9 million. Jupiter Neurosciences…- benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers INVO Fertility (NASDAQ:IVF) stock moved upwards by 13.1% to $1.73 during Monday's after-market session. The company's market cap stands at $1.7 million. The company's, Q2 earnings came out…
- benzinga.com Exicure Plans To Issue 172,058 Common Shares To GPCR Therapeutics During This Month To Settle $1M Clinical Milestone Payment Obligation Exicure, Inc. (NASDAQ:XCUR) ("Exicure" or the "Company") today announced that it expects to issue 172,058 shares of its common stock to GPCR Therapeutics, Inc. ("GPCR Therapeutics") during August
globenewswire.com Exicure to Settle GPCR Therapeutics Clinical Milestone Payment Through Equity Issuance WILMINGTON, Del., Aug. 03, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (“Exicure” or the “Company”) today announced that it expects to issue 172,058 shares of its common stock to GPCR…
benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session Gainers Zhengye Biotechnology (NASDAQ:ZYBT) shares increased by 322.6% to $2.95 during Monday's regular session. The company's market cap stands at $33.0 million. Advanced Biomed (NASDAQ:ADVB) stock…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session Gainers AtaiBeckley (NASDAQ:ATAI) stock rose 34.3% to $7.2 during Thursday's pre-market session. The market value of their outstanding shares is at $1.9 billion. Agape ATP (NASDAQ:ATPC) shares moved…
- benzinga.com 12 Health Care Stocks Moving In Wednesday's After-Market Session Gainers Agape ATP (NASDAQ:ATPC) shares rose 17.5% to $2.96 during Wednesday's after-market session. The market value of their outstanding shares is at $2.6 million. China Pharma Holding (AMEX:CPHI)…
benzinga.com Why Aehr Test Systems Shares Are Trading Higher By Around 30%; Here Are 20 Stocks Moving Premarket Shares of Aehr Test Systems (NASDAQ: AEHR) jumped 29.6% to $93.30 in pre-market trading. Aehr Test Systems beats Q4 estimates and issues FY27 guidance above estimates.- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Exicure (NASDAQ:XCUR) stock rose 38.4% to $2.38 during Tuesday's after-market session. The market value of their outstanding shares is at $10.5 million. Catheter Precision (AMEX:VTAK) stock…
globenewswire.com Exicure Announces Board and Committee Changes WILMINGTON, Del., June 30, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) ("Exicure" or the "Company") today announced changes to its Board of Directors and Board committees following actions…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session Gainers Quoin Pharmaceuticals (NASDAQ:QNRX) shares rose 40.3% to $4.56 during Tuesday's after-market session. The market value of their outstanding shares is at $8.8 million. Mobile-health Network…
benzinga.com 12 Health Care Stocks Moving In Monday's After-Market Session Gainers Catheter Precision (AMEX:VTAK) shares rose 78.2% to $1.55 during Monday's after-market session. The company's market cap stands at $2.2 million. Allarity Therapeutics (NASDAQ:ALLR) stock…
benzinga.com Exicure Receives Nasdaq Noncompliance Notice, Gets Time Through July 20 To Regain Compliance Exicure, Inc. (NASDAQ:XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") on June 5, 2026…
globenewswire.com Exicure Announces Receipt of Nasdaq Notice Regarding Minimum Stockholders’ Equity Requirement WILMINGTON, Del. , June 10, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) (the "Company") today announced that it received a notification letter from the Listing Qualifications Department of…- benzinga.com 12 Health Care Stocks Moving In Thursday's After-Market Session
globenewswire.com Exicure Announces Receipt of Nasdaq Delinquency Notice and Filing of Form 10-Q Exicure announced receipt of a Nasdaq notice related to the delayed filing of its Form 10-Q and confirmed that the Form 10-Q was filed on May 29, 2026.
benzinga.com Exicure Q1 EPS $(0.29) Down From $0.49 YoY Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.29) per share. This is a 159.18 percent decrease over earnings of $0.49 per share from the same period last year.
globenewswire.com Exicure Announces Co-Development Agreement with Adbiotech for Burixafor (GPC-100) CHICAGO, April 22, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR) today announced that it has entered into a co-development agreement with Adbiotech Co. , Ltd. (KOSDAQ: 179530), a Korea-based…- benzinga.com 12 Health Care Stocks Moving In Thursday's Pre-Market Session
benzinga.com Exicure Reaches Settlement In Shareholder Derivative Lawsuit, Agrees To Governance Reforms And $675K Legal Fee Payment Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the following notice:TO: ALL RECORD HOLDERS AND BENEFICIAL OWNERS…
globenewswire.com Summary Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions REDWOOD CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today released the…- benzinga.com Exicure Q4 EPS $(0.22) Up From $(3.39) YoY. Exicure (NASDAQ:XCUR) reported quarterly losses of $(0.22) per share. This is a 93.51 percent increase over losses of $(3.39) per share from the same period last year.
globenewswire.com Exicure, Inc. Reports Full Year 2025 Financial Results REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.- globenewswire.com Exicure, Inc. Reports Full Year 2025 Financial Results REDWOOD CITY, Calif., March 25, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR, the “Company”) releases the following financial results for the year ended December 31, 2025.
- benzinga.com On Feb 11, The Board Of Directors Of Exicure Appointed Jung Soo Kim As CEO And President; Appointed Gyuyeob Lee As Interim CFO; Andy Yoo Resigns As CEO And President; Seung Ik Baik Resigned As CFO On February 11, 2026, the board of directors (the "Board") of Exicure, Inc. (the "Company") appointed Jung Soo Kim as the Chief Executive Officer and President of the Company, and also appointed…
globenewswire.com Exicure Announces Publication in Annals of Hematology Highlighting Rapid Stem Cell Mobilization with Burixafor in Patients with Multiple Myeloma and Lymphoma Undergoing Transplant Phase 2 data demonstrate differentiated CXCR4 inhibition kinetics enabling same-day cell collection, with rapid lymphocyte mobilization supporting potential therapeutic applications beyond transplant…- benzinga.com 12 Health Care Stocks Moving In Tuesday's After-Market Session
- benzinga.com 12 Health Care Stocks Moving In Monday's Intraday Session
globenewswire.com Exicure to Present Data from Burixafor Phase 2 Trial at the 2026 Tandem Meetings REDWOOD CITY, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced that it…
defenseworld.net Exicure, Inc. (NASDAQ:XCUR) Short Interest Down 42.7% in December Exicure, Inc. (NASDAQ: XCUR - Get Free Report) was the recipient of a significant decline in short interest in the month of December. As of December 31st, there was short interest totaling 139,368…
benzinga.com Argenx, ServiceNow And Other Big Stocks Moving Lower In Monday's Pre-Market Session 
benzinga.com Why MindWalk Holdings Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket - benzinga.com 12 Health Care Stocks Moving In Wednesday's Intraday Session
- benzinga.com 12 Health Care Stocks Moving In Wednesday's Pre-Market Session
benzinga.com Crude Oil Down 1%; AutoZone Shares Dip After Q1 Results - benzinga.com 12 Health Care Stocks Moving In Tuesday's Intraday Session
benzinga.com Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial Exicure, Inc. (NASDAQ: XCUR) stock is trading higher on Tuesday. Its session volume was 13.62 million, compared with the average volume of 151.41 thousand, according to data from Benzinga Pro.
benzinga.com Exicure Rally Fueled By Rapid Cell-Boosting Results In Blood Cancer Trial Exicure shares trade higher after Phase 2 data show nearly 90% of patients reached key cell collection targets using its burixafor combination in multiple myeloma.
benzinga.com Dow Surges Over 100 Points; Campbell's Posts Upbeat Earnings 
finbold.com This BlackRock stock just rocketed 70% Exicure (NASDAQ: XCUR), a clinical-stage biotechnology company specializing in next-generation stem-cell mobilization therapies, has staged a massive rally as investors reacted to the company's new…
benzinga.com Market-Moving News for December 9th XCUR: 176% | Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte…- benzinga.com 12 Health Care Stocks Moving In Tuesday's Pre-Market Session
benzinga.com Why Mama's Creations Shares Are Trading Higher By Over 13%; Here Are 20 Stocks Moving Premarket 
benzinga.com Exicure Reports Phase 2 Results For Burixafor Combo In Multiple Myeloma; Achieves 90% Primary Endpoint In HPC Mobilization Ahead Of AHCT Exicure, Inc. (NASDAQ:XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive results from its completed Phase 2 trial evaluating…
globenewswire.com Exicure Presents Positive Topline Phase 2 Data for Burixafor in Multiple Myeloma at 2025 ASH Annual Meeting REDWOOD CITY, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Exicure, Inc. (Nasdaq: XCUR), a clinical-stage biotechnology company developing therapeutics for hematologic diseases, today announced positive…